All Evaluable Patients | Placebo | Orelabrutinib | Orelabrutinib | Orelabrutinib |
---|---|---|---|---|
50 mg | 80 mg | 100 mg | ||
N=55 | 14 | 14 | 13 | 14 |
SRI-4 response, n (%) | 5 (35.7%) | 7 (50.0%) | 8 (61.5%) | 9 (64.3%) |
Treatment difference vs. PBO (%) | 14.3% | 25.8% | 28.6% | |
SLEDAI-2K≥8, N=39 | 10 | 10 | 10 | 9 |
SRI-4 response, n (%) | 3 (30.0%) | 7 (70.0%) | 7 (70.0%) | 6 (66.7%) |
Treatment difference vs. PBO (%) | 40.0% | 40.0% | 36.7% |
Note: All evaluable patients at week 12 efficacy data were included in the efficacy analysis.